{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T13:45:26Z","timestamp":1781790326858,"version":"3.54.5"},"reference-count":119,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2013,9,6]],"date-time":"2013-09-06T00:00:00Z","timestamp":1378425600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["CNS Drugs"],"published-print":{"date-parts":[[2013,11]]},"DOI":"10.1007\/s40263-013-0105-7","type":"journal-article","created":{"date-parts":[[2013,9,5]],"date-time":"2013-09-05T11:31:18Z","timestamp":1378380678000},"page":"879-911","source":"Crossref","is-referenced-by-count":81,"title":["A Review of the Pharmacology, Efficacy and Tolerability of Recently Approved and Upcoming Oral Antipsychotics: An Evidence-Based Medicine Approach"],"prefix":"10.1007","volume":"27","author":[{"given":"Leslie","family":"Citrome","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,9,6]]},"reference":[{"issue":"6","key":"105_CR1","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1111\/j.1742-1241.2011.02669.x","volume":"65","author":"L Citrome","year":"2011","unstructured":"Citrome L. Evidence-based medicine: it\u2019s not just about the evidence. Int J Clin Pract. 2011;65(6):634\u20135.","journal-title":"Int J Clin Pract"},{"issue":"7023","key":"105_CR2","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1136\/bmj.312.7023.71","volume":"312","author":"DL Sackett","year":"1996","unstructured":"Sackett DL, Rosenberg WM, Gray JA, et al. Evidence based medicine: what it is and what it isn\u2019t. BMJ. 1996;312(7023):71\u20132.","journal-title":"BMJ"},{"issue":"3","key":"105_CR3","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1111\/j.1742-1241.2009.02014.x","volume":"63","author":"L Citrome","year":"2009","unstructured":"Citrome L, Ketter TA. Teaching the philosophy and tools of evidence-based medicine: misunderstandings and solutions. Int J Clin Pract. 2009;63(3):353\u20139.","journal-title":"Int J Clin Pract"},{"issue":"12","key":"105_CR4","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1517\/14656560903061309","volume":"10","author":"J Volavka","year":"2009","unstructured":"Volavka J, Citrome L. Oral antipsychotics for the treatment of schizophrenia: heterogeneity in efficacy and tolerability should drive decision-making. Expert Opin Pharmacother. 2009;10(12):1917\u201328.","journal-title":"Expert Opin Pharmacother"},{"issue":"6","key":"105_CR5","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1111\/j.1600-0447.2008.01194.x","volume":"117","author":"L Citrome","year":"2008","unstructured":"Citrome L. Compelling or irrelevant? Using number needed to treat can help decide. Acta Psychiatr Scand. 2008;117(6):412\u20139.","journal-title":"Acta Psychiatr Scand"},{"issue":"5","key":"105_CR6","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1111\/ijcp.12142","volume":"67","author":"L Citrome","year":"2013","unstructured":"Citrome L, Ketter TA. When does a difference make a difference? Interpretation of number needed to treat, number needed to harm, and likelihood to be helped or harmed. Int J Clin Pract. 2013;67(5):407\u201311.","journal-title":"Int J Clin Pract"},{"issue":"2 Suppl 1","key":"105_CR7","doi-asserted-by":"crossref","first-page":"S20","DOI":"10.1097\/JCP.0b013e318169d4ce","volume":"28","author":"AJ Cutler","year":"2008","unstructured":"Cutler AJ, Kalali AH, Weiden PJ, et al. Four-week, double-blind, placebo- and ziprasidone-controlled trial of\u00a0iloperidone\u00a0in patients with acute exacerbations of schizophrenia. J Clin Psychopharmacol. 2008;28(2 Suppl 1):S20\u20138.","journal-title":"J Clin Psychopharmacol"},{"issue":"2 Suppl 1","key":"105_CR8","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1097\/JCP.0b013e3181692787","volume":"28","author":"SG Potkin","year":"2008","unstructured":"Potkin SG, Litman RE, Torres R, et al. Efficacy of iloperidone in the treatment of schizophrenia: initial phase 3 studies. J Clin Psychopharmacol. 2008;28(2 Suppl 1):S4\u201311.","journal-title":"J Clin Psychopharmacol"},{"issue":"2 Suppl 1","key":"105_CR9","doi-asserted-by":"crossref","first-page":"S12","DOI":"10.1097\/JCP.0b013e3181694f5a","volume":"28","author":"PJ Weiden","year":"2008","unstructured":"Weiden PJ, Cutler AJ, Polymeropoulos MH, et al. Safety profile of iloperidone: a pooled analysis of 6-week acute-Phase pivotal trials. J Clin Psychopharmacol. 2008;28(2 Suppl 1):S12\u20139.","journal-title":"J Clin Psychopharmacol"},{"issue":"2 Suppl 1","key":"105_CR10","doi-asserted-by":"crossref","first-page":"S29","DOI":"10.1097\/JCP.0b013e318169cca7","volume":"28","author":"JM Kane","year":"2008","unstructured":"Kane JM, Lauriello J, Laska E, et al. Long-term efficacy and safety of iloperidone: results from 3 clinical trials for the treatment of schizophrenia. J Clin Psychopharmacol. 2008;28(2 Suppl 1):S29\u201335.","journal-title":"J Clin Psychopharmacol"},{"issue":"1","key":"105_CR11","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1017\/S1092852912000764","volume":"18","author":"AJ Cutler","year":"2013","unstructured":"Cutler AJ, Kalali AH, Mattingly GW, et al. Long-term safety and tolerability of iloperidone: results from a 25-week, open-label extension trial. CNS Spectr. 2013;18(1):43\u201354.","journal-title":"CNS Spectr"},{"issue":"10","key":"105_CR12","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.4088\/JCP.v68n1004","volume":"68","author":"SG Potkin","year":"2007","unstructured":"Potkin SG, Cohen M, Panagides J. Efficacy and tolerability of asenapine in acute schizophrenia: a placebo- and risperidone-controlled trial. J Clin Psychiatry. 2007;68(10):1492\u2013500.","journal-title":"J Clin Psychiatry"},{"issue":"2","key":"105_CR13","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1097\/JCP.0b013e3181d35d6b","volume":"30","author":"JM Kane","year":"2010","unstructured":"Kane JM, Cohen M, Zhao J, et al. Efficacy and safety of asenapine in a placebo- and haloperidol-controlled trial in patients with acute exacerbation of schizophrenia. J Clin Psychopharmacol. 2010;30(2):106\u201315.","journal-title":"J Clin Psychopharmacol"},{"issue":"3","key":"105_CR14","doi-asserted-by":"crossref","first-page":"349","DOI":"10.4088\/JCP.10m06306","volume":"72","author":"JM Kane","year":"2011","unstructured":"Kane JM, Mackle M, Snow-Adami L, et al. A randomized placebo-controlled trial of asenapine for the prevention of relapse of schizophrenia after long-term treatment. J Clin Psychiatry. 2011;72(3):349\u201355.","journal-title":"J Clin Psychiatry"},{"issue":"4","key":"105_CR15","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1055\/s-0030-1248313","volume":"43","author":"J Schoemaker","year":"2010","unstructured":"Schoemaker J, Naber D, Vrijland P, et al. Long-term assessment of Asenapine vs. Olanzapine in patients with schizophrenia or schizoaffective disorder. Pharmacopsychiatry. 2010;43(4):138\u201346.","journal-title":"Pharmacopsychiatry"},{"issue":"5","key":"105_CR16","first-page":"196","volume":"45","author":"J Schoemaker","year":"2012","unstructured":"Schoemaker J, Stet L, Vrijland P, et al. Long-term efficacy and safety of asenapine or olanzapine in patients with schizophrenia or schizoaffective disorder: an extension study. Pharmacopsychiatry. 2012;45(5):196\u2013203.","journal-title":"Pharmacopsychiatry"},{"issue":"1","key":"105_CR17","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1097\/JCP.0b013e31823f880a","volume":"32","author":"RW Buchanan","year":"2012","unstructured":"Buchanan RW, Panagides J, Zhao J, et al. Asenapine versus olanzapine in people with persistent negative symptoms of schizophrenia. J Clin Psychopharmacol. 2012;32(1):36\u201345.","journal-title":"J Clin Psychopharmacol"},{"issue":"7","key":"105_CR18","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1111\/j.1399-5618.2009.00748.x","volume":"11","author":"RS McIntyre","year":"2009","unstructured":"McIntyre RS, Cohen M, Zhao J, et al. A 3-week, randomized, placebo-controlled trial of asenapine in the treatment of acute mania in bipolar mania and mixed states. Bipolar Disord. 2009;11(7):673\u201386.","journal-title":"Bipolar Disord"},{"issue":"8","key":"105_CR19","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1111\/j.1399-5618.2009.00749.x","volume":"11","author":"RS McIntyre","year":"2009","unstructured":"McIntyre RS, Cohen M, Zhao J, et al. Asenapine versus olanzapine in acute mania: a double-blind extension study. Bipolar Disord. 2009;11(8):815\u201326.","journal-title":"Bipolar Disord"},{"issue":"3","key":"105_CR20","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.jad.2010.04.005","volume":"126","author":"RS McIntyre","year":"2010","unstructured":"McIntyre RS, Cohen M, Zhao J, et al. Asenapine for long-term treatment of bipolar disorder: a double-blind 40-week extension study. J Affect Disord. 2010;126(3):358\u201365.","journal-title":"J Affect Disord"},{"issue":"1\u20132","key":"105_CR21","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.jad.2009.12.028","volume":"122","author":"RS McIntyre","year":"2010","unstructured":"McIntyre RS, Cohen M, Zhao J, et al. Asenapine in the treatment of acute mania in bipolar I disorder: a randomized, double-blind, placebo-controlled trial. J Affect Disord. 2010;122(1\u20132):27\u201338.","journal-title":"J Affect Disord"},{"issue":"1","key":"105_CR22","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1097\/JCP.0b013e31823f872f","volume":"32","author":"A Szegedi","year":"2012","unstructured":"Szegedi A, Calabrese JR, Stet L, et al. Asenapine\u00a0as adjunctive treatment for acute mania associated with bipolar disorder: results of a 12-week core study and 40-week extension. J Clin Psychopharmacol. 2012;32(1):46\u201355.","journal-title":"J Clin Psychopharmacol"},{"issue":"3","key":"105_CR23","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1007\/s00213-012-2838-2","volume":"225","author":"M Ogasa","year":"2013","unstructured":"Ogasa M, Kimura T, Nakamura M, et al. Lurasidone in the treatment of schizophrenia: a 6-week, placebo-controlled study. Psychopharmacology (Berl). 2013;225(3):519\u201330.","journal-title":"Psychopharmacology (Berl)"},{"issue":"6","key":"105_CR24","doi-asserted-by":"crossref","first-page":"829","DOI":"10.4088\/JCP.08m04905","volume":"70","author":"M Nakamura","year":"2009","unstructured":"Nakamura M, Ogasa M, Guarino J, et al. Lurasidone in the treatment of acute schizophrenia: a double-blind, placebo-controlled trial. J Clin Psychiatry. 2009;70(6):829\u201336.","journal-title":"J Clin Psychiatry"},{"issue":"5","key":"105_CR25","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1016\/j.jpsychires.2013.01.020","volume":"47","author":"HA Nasrallah","year":"2013","unstructured":"Nasrallah HA, Silva R, Phillips D, et al. Lurasidone for the treatment of acutely psychotic patients with schizophrenia: a 6-week, randomized, placebo-controlled study. J Psychiatr Res. 2013;47(5):670\u20137.","journal-title":"J Psychiatr Res"},{"issue":"9","key":"105_CR26","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1176\/appi.ajp.2011.10060907","volume":"168","author":"HY Meltzer","year":"2011","unstructured":"Meltzer HY, Cucchiaro J, Silva R, et al. Lurasidone in the treatment of schizophrenia: a randomized, double-blind, placebo- and olanzapine-controlled study. Am J Psychiatry. 2011;168(9):957\u201367.","journal-title":"Am J Psychiatry"},{"key":"105_CR27","doi-asserted-by":"crossref","unstructured":"Stahl SM, Cucchiaro J, Simonelli D, et al. Effectiveness of lurasidone for patients with schizophrenia following 6\u00a0weeks of acute treatment with lurasidone, olanzapine, or placebo: a 6-month, open-label, extension study. J Clin Psychiatry. 2013;74(5):507-15","DOI":"10.4088\/JCP.12m08084"},{"issue":"2","key":"105_CR28","doi-asserted-by":"crossref","first-page":"170","DOI":"10.4088\/JCP.12m07992","volume":"74","author":"JP McEvoy","year":"2013","unstructured":"McEvoy JP, Citrome L, Hernandez D, et al. Effectiveness of lurasidone in patients with schizophrenia or schizoaffective disorder switched from other antipsychotics: a randomized, 6-week, open-label study. J Clin Psychiatry. 2013;74(2):170\u20139.","journal-title":"J Clin Psychiatry"},{"issue":"1\u20133","key":"105_CR29","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.schres.2013.01.009","volume":"145","author":"A Loebel","year":"2013","unstructured":"Loebel A, Cucchiaro J, Sarma K, et al. Efficacy and safety of lurasidone 80\u00a0mg\/day and 160\u00a0mg\/day in the treatment of schizophrenia: a randomized, double-blind, placebo- and active-controlled trial. Schizophr Res. 2013;145(1\u20133):101\u20139.","journal-title":"Schizophr Res"},{"issue":"3","key":"105_CR30","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1097\/YIC.0b013e32835281ef","volume":"27","author":"L Citrome","year":"2012","unstructured":"Citrome L, Cucchiaro J, Sarma K, et al. Long-term safety and tolerability of lurasidone in schizophrenia: a 12-month, double-blind, active-controlled study. Int Clin Psychopharmacol. 2012;27(3):165\u201376.","journal-title":"Int Clin Psychopharmacol"},{"issue":"2\u20133","key":"105_CR31","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.schres.2011.04.008","volume":"132","author":"SG Potkin","year":"2011","unstructured":"Potkin SG, Ogasa M, Cucchiaro J, et al. Double-blind comparison of the safety and efficacy of lurasidone and ziprasidone in clinically stable outpatients with schizophrenia or schizoaffective disorder. Schizophr Res. 2011;132(2\u20133):101\u20137.","journal-title":"Schizophr Res"},{"issue":"1\u20133","key":"105_CR32","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.schres.2011.01.004","volume":"127","author":"PD Harvey","year":"2011","unstructured":"Harvey PD, Ogasa M, Cucchiaro J, et al. Performance and interview-based assessments of cognitive change in a randomized, double-blind comparison of lurasidone vs. ziprasidone. Schizophr Res. 2011;127(1\u20133):188\u201394.","journal-title":"Schizophr Res"},{"issue":"12","key":"105_CR33","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.4088\/JCP.11r07596","volume":"73","author":"A Szegedi","year":"2012","unstructured":"Szegedi A, Verweij P, van Duijnhoven W, et al. Meta-analyses of the efficacy of asenapine for acute schizophrenia: comparisons with placebo and other antipsychotics. J Clin Psychiatry. 2012;73(12):1533\u201340.","journal-title":"J Clin Psychiatry"},{"issue":"9","key":"105_CR34","doi-asserted-by":"crossref","first-page":"733","DOI":"10.2165\/11634500-000000000-00000","volume":"26","author":"M Hert De","year":"2012","unstructured":"De Hert M, Yu W, Detraux J, et al. Body weight and metabolic adverse effects of asenapine, iloperidone, lurasidone and paliperidone in the treatment of schizophrenia and bipolar disorder: a systematic review and exploratory meta-analysis. CNS Drugs. 2012;26(9):733\u201359.","journal-title":"CNS Drugs"},{"issue":"Suppl 1","key":"105_CR35","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1017\/S1092852912000727","volume":"17","author":"L Citrome","year":"2012","unstructured":"Citrome L. Oral antipsychotic update: a brief review of new and investigational agents for the treatment of schizophrenia. CNS Spectr. 2012;17(Suppl 1):1\u20139.","journal-title":"CNS Spectr"},{"issue":"2","key":"105_CR36","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1007\/s12325-013-0006-7","volume":"30","author":"L Citrome","year":"2013","unstructured":"Citrome L. Cariprazine in schizophrenia: clinical efficacy, tolerability, and place in therapy. Adv Ther. 2013;30(2):114\u201326.","journal-title":"Adv Ther"},{"issue":"2","key":"105_CR37","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1007\/s12325-013-0004-9","volume":"30","author":"L Citrome","year":"2013","unstructured":"Citrome L. Cariprazine in bipolar disorder: clinical efficacy, tolerability, and place in therapy. Adv Ther. 2013;30(2):102\u201313.","journal-title":"Adv Ther"},{"issue":"2","key":"105_CR38","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1517\/17425255.2013.759211","volume":"9","author":"L Citrome","year":"2013","unstructured":"Citrome L. Cariprazine : chemistry, pharmacodynamics, pharmacokinetics, and metabolism, clinical efficacy, safety, and tolerability. Expert Opin Drug Metab Toxicol. 2013;9(2):193\u2013206.","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"10","key":"105_CR39","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1007\/s12325-012-0052-6","volume":"29","author":"L Citrome","year":"2012","unstructured":"Citrome L. Lurasidone in schizophrenia: new information about dosage and place in therapy. Adv Ther. 2012;29(10):815\u201325.","journal-title":"Adv Ther"},{"issue":"2","key":"105_CR40","doi-asserted-by":"crossref","first-page":"76","DOI":"10.3371\/CSRP.6.2.5","volume":"6","author":"L Citrome","year":"2012","unstructured":"Citrome L. Lurasidone for the acute treatment of adults with schizophrenia: what is the number needed to treat, number needed to harm, and likelihood to be helped or harmed? Clin Schizophr Relat Psychoses. 2012;6(2):76\u201385.","journal-title":"Clin Schizophr Relat Psychoses"},{"issue":"3","key":"105_CR41","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1586\/ern.12.7","volume":"12","author":"JT Kantrowitz","year":"2012","unstructured":"Kantrowitz JT, Citrome L. Lurasidone for schizophrenia: what\u2019s different? Expert Rev Neurother. 2012;12(3):265\u201373.","journal-title":"Expert Rev Neurother"},{"issue":"Suppl 1","key":"105_CR42","doi-asserted-by":"crossref","first-page":"19","DOI":"10.4088\/JCP.10075su1.04","volume":"72","author":"L Citrome","year":"2011","unstructured":"Citrome L. Iloperidone: a clinical overview. J Clin Psychiatry. 2011;72(Suppl 1):19\u201323.","journal-title":"J Clin Psychiatry"},{"issue":"1","key":"105_CR43","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1002\/hup.1254","volume":"27","author":"L Citrome","year":"2012","unstructured":"Citrome L, Meng X, Hochfeld M, et al. Efficacy of iloperidone in the short-term treatment of schizophrenia: a post hoc analysis of pooled patient data from four Phase III, placebo- and active-controlled trials. Hum Psychopharmacol. 2012;27(1):24\u201332.","journal-title":"Hum Psychopharmacol"},{"issue":"1\u20133","key":"105_CR44","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.schres.2011.05.018","volume":"131","author":"L Citrome","year":"2011","unstructured":"Citrome L, Meng X, Hochfeld M. Efficacy of iloperidone in schizophrenia: a PANSS five-factor analysis. Schizophr Res. 2011;131(1\u20133):75\u201381.","journal-title":"Schizophr Res"},{"key":"105_CR45","doi-asserted-by":"crossref","first-page":"325","DOI":"10.2147\/NDT.S16077","volume":"7","author":"L Citrome","year":"2011","unstructured":"Citrome L. Role of sublingual asenapine in treatment of schizophrenia. Neuropsychiatr Dis Treat. 2011;7:325\u201339.","journal-title":"Neuropsychiatr Dis Treat"},{"issue":"2","key":"105_CR46","doi-asserted-by":"crossref","first-page":"153","DOI":"10.3810\/pgm.2011.03.2273","volume":"123","author":"L Citrome","year":"2011","unstructured":"Citrome L. Iloperidone, asenapine, and lurasidone: a brief overview of 3 new second-generation antipsychotics. Postgrad Med. 2011;123(2):153\u201362.","journal-title":"Postgrad Med"},{"issue":"4","key":"105_CR47","doi-asserted-by":"crossref","first-page":"251","DOI":"10.3371\/CSRP.4.4.5","volume":"4","author":"L Citrome","year":"2011","unstructured":"Citrome L. Lurasidone for schizophrenia: a brief review of a new second-generation antipsychotic. Clin Schizophr Relat Psychoses. 2011;4(4):251\u20137.","journal-title":"Clin Schizophr Relat Psychoses"},{"issue":"2","key":"105_CR48","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1111\/j.1742-1241.2010.02587.x","volume":"65","author":"L Citrome","year":"2011","unstructured":"Citrome L. Lurasidone for schizophrenia: a review of the efficacy and safety profile for this newly approved second-generation antipsychotic. Int J Clin Pract. 2011;65(2):189\u2013210.","journal-title":"Int J Clin Pract"},{"issue":"12","key":"105_CR49","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1517\/17425255.2010.531259","volume":"6","author":"L Citrome","year":"2010","unstructured":"Citrome L. Iloperidone: chemistry, pharmacodynamics, pharmacokinetics and metabolism, clinical efficacy, safety and tolerability, regulatory affairs, and an opinion. Expert Opin Drug Metab Toxicol. 2010;6(12):1551\u201364.","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"6","key":"105_CR50","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1111\/j.1742-1241.2010.02344.x","volume":"64","author":"L Citrome","year":"2010","unstructured":"Citrome L. Iloperidone redux: a dissection of the Drug Approval Package for this newly commercialised second-generation antipsychotic. Int J Clin Pract. 2010;64(6):707\u201318.","journal-title":"Int J Clin Pract"},{"issue":"12","key":"105_CR51","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1111\/j.1742-1241.2009.02228.x","volume":"63","author":"L Citrome","year":"2009","unstructured":"Citrome L. Asenapine for schizophrenia and bipolar disorder: a review of the efficacy and safety profile for this newly approved sublingually absorbed second-generation antipsychotic. Int J Clin Pract. 2009;63(12):1762\u201384.","journal-title":"Int J Clin Pract"},{"issue":"8","key":"105_CR52","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1111\/j.1742-1241.2009.02142.x","volume":"63","author":"L Citrome","year":"2009","unstructured":"Citrome L. Iloperidone for schizophrenia: a review of the efficacy and safety profile for this newly commercialised second-generation antipsychotic. Int J Clin Pract. 2009;63(8):1237\u201348.","journal-title":"Int J Clin Pract"},{"key":"105_CR53","unstructured":"Novartis Pharmaceuticals Corporation. Fanapt (iloperidone) tablets. Product label. January 2013. http:\/\/www.pharma.us.novartis.com\/product\/pi\/pdf\/fanapt.pdf . Accessed 7 April 2013."},{"key":"105_CR54","unstructured":"Merck & Co., Inc. Saphris (asenapine) sublingual tablets. Product label. March 2013. http:\/\/www.merck.com\/product\/usa\/pi_circulars\/s\/saphris\/saphris_pi.pdf . Accessed 7 April 2013."},{"key":"105_CR55","unstructured":"Sunovion Pharmaceuticals Inc. Latuda (lurasidone hydrochloride) tablets. Product label. July 2013. http:\/\/www.latuda.com\/LatudaPrescribingInformation.pdf . Accessed 14 August 2013."},{"issue":"Suppl","key":"105_CR56","first-page":"S170","volume":"36","author":"HY Meltzer","year":"2011","unstructured":"Meltzer HY, Gawryl M, Ward S, et al. EVP-6124, an alpha-7 nicotinic partial agonist, produces positive effects on cognition, clinical function, and negative symptoms in patients with chronic schizophrenia on stable antipsychotic therapy. Neuropsychopharmacology. 2011;36(Suppl):S170\u20131.","journal-title":"Neuropsychopharmacology"},{"key":"105_CR57","unstructured":"Lundbeck H, A\/S. Zicronapine shows significant positive data in clinical phase II in the treatment of patients with schizophrenia \u2013 planning for continued clinical work. Press release No. 392 18 December 2009. http:\/\/investor.lundbeck.com\/releasedetail.cfm?ReleaseID=608605 . Accessed 17 April 2013."},{"issue":"Suppl. 11","key":"105_CR58","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1017\/S1092852900025086","volume":"9","author":"DK Shayegan","year":"2004","unstructured":"Shayegan DK, Stahl SM. Atypical antipsychotics: matching receptor profile to individual patient\u2019s clinical profile. CNS Spectr. 2004;9(Suppl. 11):6\u201314.","journal-title":"CNS Spectr"},{"issue":"9657","key":"105_CR59","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(08)61764-X","volume":"373","author":"S Leucht","year":"2009","unstructured":"Leucht S, Corves C, Arbter D, et al. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet. 2009;373(9657):31\u201341.","journal-title":"Lancet"},{"issue":"2","key":"105_CR60","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1176\/appi.ajp.2008.08030368","volume":"166","author":"S Leucht","year":"2009","unstructured":"Leucht S, Komossa K, Rummel-Kluge C, et al. A meta-analysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophrenia. Am J Psychiatry. 2009;166(2):152\u201363.","journal-title":"Am J Psychiatry"},{"issue":"4","key":"105_CR61","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1038\/sj.mp.4002136","volume":"14","author":"S Leucht","year":"2009","unstructured":"Leucht S, Arbter D, Engel RR, et al. How effective are second-generation antipsychotic drugs? A meta-analysis of placebo-controlled trials. Mol Psychiatry. 2009;14(4):429\u201347.","journal-title":"Mol Psychiatry"},{"key":"105_CR62","unstructured":"Pfizer Inc. Geodon (ziprasidone HCl) capsules. Product label. March 2013. http:\/\/labeling.pfizer.com\/ShowLabeling.aspx?id=584 . Accessed 9 April 2013."},{"issue":"3","key":"105_CR63","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1517\/14740338.2011.560114","volume":"10","author":"L Citrome","year":"2011","unstructured":"Citrome L. Drug safety evaluation of\u00a0ziprasidone. Expert Opin Drug Saf. 2011;10(3):437\u201348.","journal-title":"Expert Opin Drug Saf"},{"issue":"1","key":"105_CR64","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1097\/JCP.0b013e31827c0314","volume":"33","author":"SG Potkin","year":"2013","unstructured":"Potkin SG, Preskorn S, Hochfeld M, et al. A Thorough QTc study of 3 doses of\u00a0iloperidone\u00a0including metabolic inhibition via CYP2D6 and\/or CYP3A4 and a comparison to quetiapine and ziprasidone. J Clin Psychopharmacol. 2013;33(1):3\u201310.","journal-title":"J Clin Psychopharmacol"},{"key":"105_CR65","unstructured":"United States Food and Drug Administration. Saphris (Asenapine) Sublingual Tablets. Briefing Book. 30 July 2009. http:\/\/www.fda.gov\/downloads\/AdvisoryCommittees\/CommitteesMeetingMaterials\/Drugs\/PsychopharmacologicDrugsAdvisoryCommittee\/UCM173877.pdf . Accessed 9 April 2013."},{"key":"105_CR66","unstructured":"Schering-Plough Research Institute. Saphris (Asenapine) Sublingual Tablets. Briefing Document (Background Package). 30 July 2009. http:\/\/www.fda.gov\/downloads\/AdvisoryCommittees\/CommitteesMeetingMaterials\/Drugs\/PsychopharmacologicDrugsAdvisoryCommittee\/UCM173876.pdf . Accessed 9 April 2013."},{"issue":"1","key":"105_CR67","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.neuroscience.2007.07.043","volume":"149","author":"SJ Ballaz","year":"2007","unstructured":"Ballaz SJ, Akil H, Watson SJ. The 5-HT7 receptor: role in novel object discrimination and relation to novelty-seeking behavior. Neuroscience. 2007;149(1):192\u2013202.","journal-title":"Neuroscience"},{"issue":"11","key":"105_CR68","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1177\/0091270009344855","volume":"49","author":"S Chapel","year":"2009","unstructured":"Chapel S, Hutmacher MM, Haig G, et al. Exposure-response analysis in patients with schizophrenia to assess the effect of\u00a0asenapine\u00a0on QTc prolongation. J Clin Pharmacol. 2009;49(11):1297\u2013308.","journal-title":"J Clin Pharmacol"},{"issue":"3","key":"105_CR69","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/S0006-3223(02)01643-8","volume":"53","author":"P Blier","year":"2003","unstructured":"Blier P, Ward NM. Is there a role for 5-HT1A agonists in the treatment of depression? Biol Psychiatry. 2003;53(3):193\u2013203.","journal-title":"Biol Psychiatry"},{"issue":"1","key":"105_CR70","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1111\/j.1755-5949.2010.00211.x","volume":"17","author":"Y Ohno","year":"2011","unstructured":"Ohno Y. Therapeutic role of 5-HT1A receptors in the treatment of schizophrenia and Parkinson\u2019s disease. CNS Neurosci Ther. 2011;17(1):58\u201365.","journal-title":"CNS Neurosci Ther"},{"issue":"8","key":"105_CR71","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1007\/s12325-009-0055-0","volume":"26","author":"L Citrome","year":"2009","unstructured":"Citrome L. Using oral ziprasidone effectively: the food effect and dose-response. Adv Ther. 2009;26(8):739\u201348.","journal-title":"Adv Ther"},{"key":"105_CR72","unstructured":"United States Food and Drug Administration. Drug Approval Package. Latuda (lurasidone hydrochloride) Tablets. 3 December 2010. http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2010\/200603Orig1s000TOC.cfm . Accessed 10 April 2013."},{"key":"105_CR73","unstructured":"Dainippon Sumitomo Pharma. Dainippon Sumitomo Pharma announces Pan-Asia study results for lurasidone, an atypical antipsychotic agent, in the treatment of schizophrenia. Press Release 11 May 2011. http:\/\/www.ds-pharma.com\/news\/pdf\/ene20110511_3.pdf . Accessed 10 April 2013."},{"key":"105_CR74","doi-asserted-by":"crossref","unstructured":"Loebel A, Cucchiaro J, Xu J, et al. Effectiveness of lurasidone vs. quetiapine XR for relapse prevention in schizophrenia: a 12-month, double-blind, noninferiority study. Schizophr Res. 2013;147(1):95-102","DOI":"10.1016\/j.schres.2013.03.013"},{"key":"105_CR75","unstructured":"Silva R, Correll C, Simonelli D, et al. Long-term safety and effectiveness of lurasidone in schizophrenia: results of a 22-month, open-label extension study. Poster Presentation NR6-37; American Psychiatric Association 165th Annual Meeting; May 5\u20139, 2012; Philadelphia, Pennsylvania."},{"key":"105_CR76","unstructured":"Loebel A, Cucchiaro J, Silva R, et al. Lurasidone monotherapy for the treatment of bipolar I depression: results of a 6-week, double-blind, placebo-controlled study. Poster Presentation NR4-58; American Psychiatric Association; 165th Annual Meeting; May 5\u20139, 2012; Philadelphia, Pennsylvania."},{"key":"105_CR77","unstructured":"Loebel A, Cucchiaro J, Silva R, et al. Lurasidone adjunctive to lithium or valproate for the treatment of bipolar I depression: results of a 6-week, double-blind, placebo-controlled study. Poster Presentation NR4-29; American Psychiatric Association; 165th Annual Meeting; May 5\u20139, 2012; Philadelphia, Pennsylvania."},{"key":"105_CR78","unstructured":"Sunovion Pharmaceuticals Inc. Sunovion Pharmaceuticals Announces FDA Approval of Latuda\u00ae (lurasidone HCl) as Monotherapy and Adjunctive Therapy in Adult Patients with Bipolar Depression. Press release 28 June 2013. http:\/\/www.ds-pharma.com\/pdf_view.php?id=306 . Accessed 10 July 2013."},{"issue":"4","key":"105_CR79","doi-asserted-by":"crossref","first-page":"427","DOI":"10.2147\/nedt.2006.2.4.427","volume":"2","author":"L Citrome","year":"2006","unstructured":"Citrome L. A review of aripiprazole in the treatment of patients with schizophrenia or bipolar I disorder. Neuropsychiatr Dis Treat. 2006;2(4):427\u201343.","journal-title":"Neuropsychiatr Dis Treat"},{"issue":"6","key":"105_CR80","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/j.neuint.2011.07.002","volume":"59","author":"I Gyertyan","year":"2011","unstructured":"Gyertyan I, Kiss B, Saghy K, et al. Cariprazine (RGH-188), a potent D3\/D2 dopamine receptor partial agonist, binds to dopamine D3 receptors in vivo and shows antipsychotic-like and procognitive effects in rodents. Neurochem Int. 2011;59(6):925\u201335.","journal-title":"Neurochem Int"},{"key":"105_CR81","unstructured":"Litman R, Papadakis K, Durgam S, et al. Use of cariprazine in the treatment of schizophrenia: a proof-of-concept trial. Poster Presentation 61; 60th Institute on Psychiatric Services of the American Psychiatric Association; October 2\u20135, 2008; Chicago, IL."},{"key":"105_CR82","unstructured":"Bose A, Li D, Migliore R, et al. The efficacy and safety of the novel antipsychotic cariprazine in acute exacerbation of schizophrenia. Poster Presentation I-73; NCDEU 50th Annual Meeting; June 14\u201317, 2010; Boca Raton, Florida."},{"key":"105_CR83","unstructured":"Zukin, SR, Kane J, Cutler, AJ, et al. Efficacy and safety of cariprazine in acute exacerbation of schizophrenia: a phase III, international, randomized, double-blind, placebo-controlled trial. Poster Presentation W9; American College of Neuropsychopharmacology 51st Annual Meeting; December 2\u20136, 2012; Hollywood, Florida."},{"key":"105_CR84","unstructured":"Forest Laboratories, Inc. and Gedeon Richter Plc. Announce Results from Two Positive Phase III Trials with the Investigational Antipsychotic Cariprazine for the Treatment of Schizophrenia [press release]. Forest Laboratories, Inc.; 28 Feb 2012. http:\/\/news.frx.com\/press-release\/rd-news\/forestlaboratoriesinc-and-gedeon-richter-plc-announceresultstwo-positive-p . Accessed 16 April 2013."},{"key":"105_CR85","unstructured":"Knesevich MA, Papadakis K, Bose A, et al. The efficacy and tolerability of cariprazine in acute mania associated with bipolar disorder: a Phase II trial. Poster Presentation NR1-49; American Psychiatric Association 162nd Annual Meeting; 16\u201321 May 2009; San Francisco, California."},{"key":"105_CR86","unstructured":"Starace A, Bose A, Wang Q, et al. Cariprazine in the treatment of acute mania in bipolar disorder: a double-blind, placebo-controlled, Phase III trial. Poster Presentation NR9-42; American Psychiatric Association 165th Annual Meeting; 5\u20139 May 2012;Philadelphia, Pennsylvania."},{"key":"105_CR87","unstructured":"Forest Laboratories, Inc. and Gedeon Richter Plc announce positive phase III results with the investigational antipsychotic cariprazine in patients with acute mania associated with bipolar I disorder [press release]. Forest Laboratories, Inc.; 8 Feb 2012. http:\/\/news.frx.com\/press-release\/product-news\/forest-laboratories-inc-and-gedeon-richter-plcannouncepositive-phase-ii . Accessed 16 April 2013."},{"key":"105_CR88","unstructured":"Cutler A, Bose A, Durgam S, et al. Safety and tolerability of cariprazine in the long-term treatment of schizophrenia: results from a 48-week extension study. Poster Presentation NR6-50; American Psychiatric Association 165th Annual Meeting; 5\u20139 May 2012; Philadelphia, Pennsylvania."},{"key":"105_CR89","unstructured":"Forest Laboratories, Inc. and Gedeon Richter Plc announce results from a phase II study of cariprazine for the treatment of bipolar depression [press release]. Forest Laboratories, Inc.; 30 Aug 2010. http:\/\/news.frx.com\/press-release\/rd-news\/forest-laboratories-inc-and-gedeon-richterplcannounce-results-phase-ii-stu-0 . Accessed 16 April 2013."},{"key":"105_CR90","unstructured":"Forest Laboratories, Inc. Forest Laboratories, Inc. and Gedeon Richter Plc. Announce results from a phase II study of cariprazine as adjunctive therapy in major depressive disorder. Press Release. 28 Feb 2011. http:\/\/news.frx.com\/press-release\/rd-news\/forest-laboratories-inc-andgedeon-richter-plc-announce-resultsphase-ii-study . Accessed 16 April 2013."},{"key":"105_CR91","unstructured":"Kikuchi T, Maeda K, Sugino, et al. Preclinical pharmacology of OPC-34712: a novel compound with dopamine D2 receptor partial agonist activity. Poster presentation; Society of Biological Psychiatry 66th Annual Meeting; May 12\u201314, 2011; San Francisco, California."},{"key":"105_CR92","unstructured":"McQuade R, Hobart M, Forbes RA, et al. A Phase II trial assessing the efficacy and safety of OPC-34712 in the acute treatment of adult schizophrenia (Study 331-07-203). Poster Presentation 140; 2011 US Psychiatric Congress; 7\u201310 Nov 2011."},{"key":"105_CR93","unstructured":"Thase M, Fava M, Hobart M, et al. Efficacy and safety of adjunctive OPC-34712 in major depressive disorder: a Phase II, randomized, placebo-controlled study. Poster Presentation NR4-65; American Psychiatric Association 164th Annual Meeting; 14\u201318 May 2011; Honolulu, Hawaii."},{"key":"105_CR94","unstructured":"Lundbeck H. A\/S. The clinical phase III programme commenced on zicronapine. 20 Jan 2011. http:\/\/investor.lundbeck.com\/releasedetail.cfm?ReleaseID=608573 . Accessed 7 April 2013."},{"issue":"2","key":"105_CR95","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1016\/j.neuropharm.2011.11.008","volume":"62","author":"D Alberati","year":"2012","unstructured":"Alberati D, Moreau JL, Lengyel J, et al. Glycine reuptake inhibitor RG1678: a pharmacological characterization of an investigational agent for the treatment of schizophrenia. Neuropharmacology. 2012;62(2):1152\u201361.","journal-title":"Neuropharmacology"},{"issue":"2","key":"105_CR96","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1097\/YCO.0b013e32835035b2","volume":"25","author":"J Kantrowitz","year":"2012","unstructured":"Kantrowitz J, Javitt DC. Glutamatergic transmission in schizophrenia: from basic research to clinical practice. Curr Opin Psychiatry. 2012;25(2):96\u2013102.","journal-title":"Curr Opin Psychiatry"},{"issue":"3","key":"105_CR97","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1038\/npp.2012.212","volume":"38","author":"M Martin-Facklam","year":"2013","unstructured":"Martin-Facklam M, Pizzagalli F, Zhou Y, et al. Glycine transporter type 1 occupancy by bitopertin: a positron emission tomography study in healthy volunteers. Neuropsychopharmacology. 2013;38(3):504\u201312.","journal-title":"Neuropsychopharmacology"},{"issue":"10","key":"105_CR98","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.1016\/j.clinthera.2012.08.010","volume":"34","author":"C Hofmann","year":"2012","unstructured":"Hofmann C, Banken L, Hahn M, et al. Evaluation of the effects of bitopertin (RG1678) on cardiac repolarization: a thorough corrected QT study in healthy male volunteers. Clin Ther. 2012;34(10):2061\u201371.","journal-title":"Clin Ther"},{"issue":"12","key":"105_CR99","doi-asserted-by":"crossref","first-page":"4603","DOI":"10.1021\/jm100210p","volume":"53","author":"E Pinard","year":"2010","unstructured":"Pinard E, Alanine A, Alberati D, et al. Selective GlyT1 inhibitors: discovery of [4-(3-fluoro-5-trifluoromethylpyridin-2-yl)piperazin-1-yl][5-methanesulfonyl-2-((S)-2,2,2-trifluoro-1-methylethoxy)phenyl]methanone (RG1678), a promising novel medicine to treat schizophrenia. J Med Chem. 2010;53(12):4603\u201314.","journal-title":"J Med Chem"},{"issue":"Suppl","key":"105_CR100","first-page":"S320","volume":"35","author":"D Umbricht","year":"2010","unstructured":"Umbricht D, Yoo K, Youssef E, et al. Glycine transporter type 1 (GlyT1) inhibitor RG1678: positive results of the proof-of-concept study for the treatment of negative symptoms in schizophrenia. Neuropsychopharmacology. 2010;35(Suppl):S320\u20131.","journal-title":"Neuropsychopharmacology"},{"issue":"Suppl 4","key":"105_CR101","first-page":"1","volume":"70","author":"DI Velligan","year":"2009","unstructured":"Velligan DI, Weiden PJ, Sajatovic M, et al. The expert consensus guideline series: adherence problems in patients with serious and persistent mental illness. J Clin Psychiatry. 2009;70(Suppl 4):1\u201346.","journal-title":"J Clin Psychiatry"},{"issue":"Suppl 1","key":"105_CR102","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1097\/01.jcp.0000142281.85207.d5","volume":"24","author":"JW Newcomer","year":"2004","unstructured":"Newcomer JW, Nasrallah HA, Loebel AD. The atypical antipsychotic therapy and metabolic issues national survey. J Clin Psychopharmacol. 2004;24(Suppl 1):S1\u20136.","journal-title":"J Clin Psychopharmacol"},{"key":"105_CR103","unstructured":"Markowitz M, Levitan B, Mohammed AF, et al. Psychiatrists\u2019 preferences for benefit and risk outcomes and formulation in schizophrenia treatments: a conjoint analysis study. Poster Presentation (PS5-05); American Psychiatric Association 64th Institute on Psychiatric Services; October 2\u20137, 2012; New York City, New York."},{"issue":"2","key":"105_CR104","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1111\/j.1527-3458.2007.00008.x","volume":"13","author":"WM Greenberg","year":"2007","unstructured":"Greenberg WM, Citrome L. Ziprasidone for schizophrenia and bipolar disorder: a review of the clinical trials. CNS Drug Rev. 2007;13(2):137\u201377.","journal-title":"CNS Drug Rev"},{"issue":"7","key":"105_CR105","doi-asserted-by":"crossref","first-page":"455","DOI":"10.2165\/11589060-000000000-00000","volume":"31","author":"L Citrome","year":"2011","unstructured":"Citrome L, Holt RI, Walker DJ, et al. Weight gain and changes in metabolic variables following olanzapine treatment in schizophrenia and bipolar disorder. Clin Drug Investig. 2011;31(7):455\u201382.","journal-title":"Clin Drug Investig"},{"issue":"11","key":"105_CR106","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1517\/14656566.2011.626767","volume":"13","author":"L Citrome","year":"2012","unstructured":"Citrome L, Nasrallah HA. On-label on the table: what the package insert informs us about the tolerability profile of oral atypical antipsychotics, and what it does not. Expert Opin Pharmacother. 2012;13(11):1599\u2013613.","journal-title":"Expert Opin Pharmacother"},{"issue":"3","key":"105_CR107","doi-asserted-by":"crossref","first-page":"229","DOI":"10.2174\/157488609789006985","volume":"4","author":"L Citrome","year":"2009","unstructured":"Citrome L. Quantifying risk: the role of absolute and relative measures in interpreting risk of adverse reactions from product labels of antipsychotic medications. Curr Drug Saf. 2009;4(3):229\u201337.","journal-title":"Curr Drug Saf"},{"issue":"4","key":"105_CR108","doi-asserted-by":"crossref","first-page":"39","DOI":"10.3810\/pgm.2010.07.2174","volume":"122","author":"L Citrome","year":"2010","unstructured":"Citrome L. Adjunctive aripiprazole, olanzapine, or quetiapine for major depressive disorder: an analysis of number needed to treat, number needed to harm, and likelihood to be helped or harmed. Postgrad Med. 2010;122(4):39\u201348.","journal-title":"Postgrad Med"},{"issue":"17","key":"105_CR109","doi-asserted-by":"crossref","first-page":"2751","DOI":"10.1517\/14656566.2011.632368","volume":"12","author":"L Citrome","year":"2011","unstructured":"Citrome L. Olanzapine-fluoxetine combination for the treatment of bipolar depression. Expert Opin Pharmacother. 2011;12(17):2751\u20138.","journal-title":"Expert Opin Pharmacother"},{"issue":"5","key":"105_CR110","doi-asserted-by":"crossref","first-page":"318","DOI":"10.3109\/15622975.2012.696143","volume":"13","author":"A Hasan","year":"2012","unstructured":"Hasan A, Falkai P, Wobrock T, et al. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, part 1: update 2012 on the acute treatment of schizophrenia and the management of treatment resistance. World J Biol Psychiatry. 2012;13(5):318\u201378.","journal-title":"World J Biol Psychiatry"},{"issue":"1","key":"105_CR111","doi-asserted-by":"crossref","first-page":"2","DOI":"10.3109\/15622975.2012.739708","volume":"14","author":"A Hasan","year":"2013","unstructured":"Hasan A, Falkai P, Wobrock T, et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 2: update 2012 on the long-term treatment of schizophrenia and management of antipsychotic-induced side effects. World J Biol Psychiatry. 2013;14(1):2\u201344.","journal-title":"World J Biol Psychiatry"},{"issue":"3","key":"105_CR112","doi-asserted-by":"crossref","first-page":"154","DOI":"10.3109\/15622975.2013.770551","volume":"14","author":"H Grunze","year":"2013","unstructured":"Grunze H, Vieta E, Goodwin GM, et al. The World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Biological Treatment of\u00a0Bipolar\u00a0Disorders: Update 2012 on the long-term treatment of\u00a0bipolar\u00a0disorder. World J Biol Psychiatry. 2013;14(3):154\u2013219.","journal-title":"World J Biol Psychiatry"},{"issue":"2","key":"105_CR113","doi-asserted-by":"crossref","first-page":"81","DOI":"10.3109\/15622970903555881","volume":"11","author":"H Grunze","year":"2010","unstructured":"Grunze H, Vieta E, Goodwin GM, et al. The World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Biological Treatment of Bipolar Disorders: Update 2010 on the treatment of acute bipolar depression. World J Biol Psychiatry. 2010;11(2):81\u2013109.","journal-title":"World J Biol Psychiatry"},{"issue":"2","key":"105_CR114","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1080\/15622970902823202","volume":"10","author":"H Grunze","year":"2009","unstructured":"Grunze H, Vieta E, Goodwin GM, et al. The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of\u00a0bipolar\u00a0disorders: update 2009 on the treatment of acute mania. World J Biol Psychiatry. 2009;10(2):85\u2013116.","journal-title":"World J Biol Psychiatry"},{"issue":"3","key":"105_CR115","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1017\/S109285291300014X","volume":"18","author":"SM Stahl","year":"2013","unstructured":"Stahl SM, Morrissette DA, Citrome L, et al. \u201cMeta-guidelines\u201d for the management of patients with schizophrenia. CNS Spectr. 2013;18(3):150\u201362.","journal-title":"CNS Spectr"},{"key":"105_CR116","doi-asserted-by":"crossref","unstructured":"Leucht S, Cipriani A, Spineli L, et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet. 2013 (Epub ahead of print).","DOI":"10.1016\/S0140-6736(13)60733-3"},{"key":"105_CR117","unstructured":"Guy W. EDCEU Assessment Manual for Psychopharmacology \u2013 Revised (DHEW Publ No ADM 76-338). Rockville, MD: U.S. Department of Health, Education, and Welfare, Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration, NIMH Psychopharmacology Research Branch, Division of Extramural Research Programs, 1976:534\u20137."},{"issue":"2","key":"105_CR118","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1038\/sj.npp.1300873","volume":"31","author":"S Leucht","year":"2006","unstructured":"Leucht S, Engel RR. The relative sensitivity of the Clinical Global Impressions Scale and the Brief Psychiatric Rating Scale in antipsychotic drug trials. Neuropsychopharmacology. 2006;31(2):406\u201312.","journal-title":"Neuropsychopharmacology"},{"issue":"1\u20133","key":"105_CR119","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.schres.2007.09.006","volume":"98","author":"SZ Levine","year":"2008","unstructured":"Levine SZ, Rabinowitz J, Engel R, et al. Extrapolation between measures of symptom severity and change: an examination of the PANSS and CGI. Schizophr Res. 2008;98(1\u20133):318\u201322.","journal-title":"Schizophr Res"}],"container-title":["CNS Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-013-0105-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40263-013-0105-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-013-0105-7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,5]],"date-time":"2022-03-05T16:03:34Z","timestamp":1646496214000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40263-013-0105-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,9,6]]},"references-count":119,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2013,11]]}},"alternative-id":["105"],"URL":"https:\/\/doi.org\/10.1007\/s40263-013-0105-7","relation":{},"ISSN":["1172-7047","1179-1934"],"issn-type":[{"value":"1172-7047","type":"print"},{"value":"1179-1934","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,9,6]]}}}